Biodesix (BDSX) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $18.0 million, up 21% year-over-year, driven by strong lung diagnostic performance and growth in Development Services.

• Diagnostic Testing revenue rose 18% to $16.3 million, with Development Services revenue up 61% to $1.7 million.

• Net loss improved by 18% to $11.1 million, reflecting higher revenues and cost controls.

• Commercial expansion reconfigured to a territory-based sales structure, causing a one-quarter delay in the commercial plan.

• Pro forma cash balance increased to $27.6 million after drawing $10 million from a term loan facility post-quarter end.

Financial highlights

• Gross margin improved to 79.4% in Q1 2025, up from 78.6% in Q1 2024.

• Operating expenses (excluding direct costs) rose 3% year-over-year to $23.4 million, mainly due to higher R&D investment.

• Adjusted EBITDA loss was $6.2 million, improving 11% year-over-year.

• Net loss per share was $0.08, compared to $0.14 in Q1 2024.

• Cash used in operations was $8.6 million, a $6.7 million improvement over Q1 2024.

Outlook and guidance

• 2025 revenue guidance revised to $80–85 million due to delayed sales team expansion.

• Expect acceleration of growth in the second half of 2025 as sales force expansion catches up.

• Adjusted EBITDA positivity targeted for Q4 2025, supported by strong gross margins and cost control.

• Plan to end 2025 with 95 sales reps and continue hiring into 2026, aiming for 120 by year-end 2026.

• Ongoing focus on expanding payer coverage, customer base, and biopharmaceutical partnerships.